Management of acute coronary syndromes: Acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology

European Heart Journal

Volumn 21, Issue 17, 2000, Pages 1406-1432

  Bertrand, M E ^a   Simoons, M L ^a   Fox, K A A ^a   Wallentin, L C ^a   Hamm, C W ^a   McFadden, E ^a   De Feyter, P J ^a   Specchia, G ^a   Ruzyllo, W ^a  

^a NONE

Author keywords

Acute coronary syndromes; Coronary bypass surgery; Non Q wave myocardial infarction; Percutaneous transluminal coronary angioplasty; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NITRATE;

FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; LONG TERM CARE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION;

ACUTE DISEASE; ARRHYTHMIA; BIOLOGICAL MARKERS; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL ISCHEMIA; RISK ASSESSMENT; SYNDROME;

EID: 0033899199     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2000.2301     Document Type: Review

References (190)

1. Davies MJ, Richardson PJWN, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 69:1993;377-381.
2. Davies M. Acute coronary thrombosis: the role of plaque disruption and its initiation and prevention. Eur Heart J. 16:1995;3-7.
3. Davies M. The composition of coronary artery plaque. N Engl J Med. 336:1997;1312-1313.
4. Eur Heart J. 17:1996;43-63.
5. Fuster VBL, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 326:1992;242-250.
6. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 90:1994;2126-2146.
7. Burke APFA, Tang AL. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 336:1997;1276-1282.
8. Farb ABA, Tang AL. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation. 93:1996;1354-1363.
9. Arbustini EDBB, Morbini P, Burke AP, Bocciarelli M, Specchia G, Virmani. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart. 82:1999;269-272.
10. Libby P. Molecular basis of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
11. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation. 90:1994;775-778.
12. Kaartinen A, Penttila A, Kovanen P. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation. 90:1994;1669-1678.
13. Kaartinen M, van der Wal A, van der Loos C. Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. J Am Coll Cardiol. 32:1998;606-612.
14. Arbustini E, De Servi S, Bramucci E. Comparison of coronary lesions obtained by directional coronary atherectomy in unstable angina, stable angina, and restenosis after either atherectomy or angioplasty. Am J Cardiol. 75:1995;675-682.
15. Arbustini E, Morbini P, De Servi S. Histopathologic features in atherectomy samples obtained from patient with unstable angina, stable angina and restenosis. Directional Atherectomy Lombardi Group. G Ital Cardiol. 26:1996;623-633.
16. Toschi V, Gallo R, Lettino M, Fallon J. Tissue factor predicts the thrombogenicity of human atherosclerotic components. Circulation. 95:1997;594-599.
17. Willerson J, Golino PEJ, Campbell W, Buja M. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation. 80:1989;198-205.
18. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol. 63:1989;114E-120E.
19. Falk E, Fuster V. Angina pectoris and disease progression [editorial; comment]. Circulation. 92:1995;2033-2035.
20. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
21. van Domburg R, van Miltenburg-van Zijl A, Veerhoeck R, Simoons M. Unstable angina: good long-term outcome after a complicated early course. J Am Coll Cardiol. 31:1998;1534-1539.
22. Lee T, Cook F, Erb R. Acute chest pain in the emergency room. Arch Int Med. 145:1985;65-69.
23. Fesmire FM, Percy RF, Bardoner JB, Wharton DR, Calhoun FB. Usefulness of automated serial 12-lead ECG monitoring during the initial emergency department evaluation of patients with chest pain. Ann Emerg Med. 31:1998;3-11.
24. Fisch C. The Clinical ECG: Sensitivity and Specificity. 1997;Elsevier Science publishers.
25. Lee T, Cook E, Weisberg M. Impact of the availability of a prior ECG on the triage of the patient with acute chest pain. J Gen Intern Med. 5:1990;381-388.
26. McCarthy B, Wong J, Selker H. Detecting acute ischemia in the emergency department. J Gen Int Med. 5:1990;365-373.
27. Rouan G, Lee T, Cook E. Clinical characteristics and outcome of acute myocardial infarction in patients with normal or nonspecific electrocardiograms. Am J Cardiol. 64:1989;1087-1092.
28. Pozen M, D'Agostino R, Selker H. A predictive instrument to improve CCU admission practices in acute ischemic heart disease. A prospective multicenter clinical trial. N Engl J Med. 310:1984;1279-1292.
29. Katus H, Looser S, Hallermayer K. Development and in vitro characterization of a new immunoassay of cardiac troponon T. Clin Chem. 38:1992;386-393.
30. Davies E, Gawad Y, Takashi M. Analytical performance and clinical utility of a sensitive immunoassay for determination of human cardiac troponin I. Clin Biochem. 30:1997;479-490.
31. Cohen M, Demers C, Gurfinkel EP. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 337:1997;447-452.
32. Campbell R, Wallentin L, Verheugt F, Turpie A. Management strategies for a better outcome in unstable coronary artery disease. Clin Cardiol. 21:1998;314-322.
33. Braunwald E, Jones RH, Mark DB. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation. 90:1994;613-622.
34. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 97:1998;1195-1206.
35. Braunwald E. Unstable angina. A classification. Circulation. 80:1989;410-414.
36. van Miltenburg-van Zijl AJ, Simoons ML, Veerhoek RJ, Bossuyt PM. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris. J Am Coll Cardiol. 25:1995;1286-1292.
37. Circulation. 89:1994;1545-1556.
38. Andersen K, Eriksson PMD. Ischaemia detected by continuous on-line vectocardiographic monitoring predicts unfavourable outcome in patients admitted with probable unstable coronary artery disease. Coron Art Dis. 7:1996;753-760.
39. Langer A, Freeman MR, Armstrong PW. ST segment shift in unstable angina: pathophysiology and association with coronary anatomy and hospital outcome. J Am Coll Cardiol. 13:1989;1495-1502.
40. Gottlieb S, Weisfeldt M, Ouyang P. Silent myocardial ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med. 314:1986;1214-1219.
41. Larsson H, Areskog M, Areskog NH. The diagnostic and prognostic importance of ambulatory ST recording compared to a predischarge exercise test after an episode of unstable angina or non-Q wave myocardial infarction. Eur Heart J. 16:1995;888-893.
42. Wilcox I, Ben Freedman S, Kelly DT, Harris PJ. Clinical significance of silent ischemia in unstable angina pectoris. Am J Cardiol. 65:1990;1313-1316.
43. Patel DJ, Holdright DR, Knight CJ. Early continuous ST segment monitoring in unstable angina: prognostic value additional to the clinical characteristics and the admission electrocardiogram. Heart. 75:1996;222-228.
44. Andersen K, Dellborg M. Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group. Am J Cardiol. 81:1998;939-944.
45. Frostfeldt GAG, Gustafsson G, Helmius G. Low molecular weight heparin (Dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction - a pilot study: Biochemical markers in Acute Coronary Syndromes (BIOMACSII). J Am Coll Cardiol. 33:1999;627-633.
46. Klootwijk P, Meij S, von Es GA. Comparison of usefulness of computer assisted continuous 48-h 3-lead with 12-lead ECG ischaemia monitoring for detection and quantitation of ischaemia in patients with unstable angina. Eur Heart J. 18:1997;931-940.
47. Klootwijk P, Meij S, Melkert R, Lenderink T, Simoons ML. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). Circulation. 98:1998;1358-1364.
48. Klootwijk P, Lenderink T, Meij S. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur Heart J. 20:1999;1101-1111.
49. Hamm CW, Ravkilde J, Gerhardt W. The prognostic value of serum troponin T in unstable angina. N Engl J Med. 327:1992;146-150.
50. Pettersson T, Ohlsson O, Tryding N. Increased CKMB (mass concentration) in patients without traditional evidence of acute myocardial infarction. A risk indicator of coronary death. Eur Heart J. 13:1992;1387-1392.
51. Ravkilde J, Hansen AB, Horder M, Jorgensen PJ, Thygesen K. Risk stratification in suspected acute myocardial infarction based on a sensitive immunoassay for serum creatine kinase isoenzyme MB. A 2.5-year follow-up study in 156 consecutive patients. Cardiology. 80:1992;143-151.
52. Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M. Prospective study of the role of cardiac troponin T in patients admitted with unstable angina. Br Med J. 313:1996;262-264.
53. Wu AH, Abbas SA, Green S. Prognostic value of cardiac troponin T in unstable angina pectoris. Am J Cardiol. 76:1995;970-972.
54. Lindahl B. Biochemical markers of myocardial damage for early diagnosis and prognosis in patients with acute coronary syndromes. Minireview based on a doctorial thesis. Ups J Med Sci. 101:1996;193-232.
55. Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation. 93:1996;1651-1657.
56. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol. 29:1997;43-48.
57. Antman EM, Tanasijevic MJ, Thompson B. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 335:1996;1342-1349.
58. Lüscher MS, Thygesen K, Ravkilde J, Heickendorff L. Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia. Circulation. 96:1997;2578-2585.
59. Galvani M, Ottani F, Ferrini D. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation. 95:1997;2053-2059.
60. Lindahl B, Andren B, Ohlsson J, Venge P, Wallentin L. Risk stratification in unstable coronary artery disease. Additive value of troponin T determinations and pre-discharge exercise tests. FRISK Study Group. Eur Heart J. 18:1997;762-770.
61. Holmvang L, Andersen K. Relative contributions of a single-admission 12-lead electrocardiogram and early 24-hour continuous electrocardiographic monitoring for early risk stratification in patients with unstable coronary artery disease. Am J Cardiol. 83:1999;667-674.
62. Dellborg M, Andersen K. Key factors in the identification of the high-risk patient with unstable coronary artery disease: clinical findings, resting 12-lead electrocardiogram, and continuous electrocardiographic monitoring. Am J Cardiol. 80:1997;35E-39E.
63. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation. 96:1997;4204-4210.
64. Hamm C, Heeschen C, Goldmann B. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin level. N Engl J Med. 340:1999;1623-1629.
65. Lancet. 354:1999;701-707.
66. Heeschen C, Hamm C, Goldmann B, Deu A, Langenbrink L, White H. Troponin concentrations for stratification of patients with acute syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 354:1999;1757-1762.
67. Becker R, Cannon C, Bovill E. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB trial). Am J Cardiol. 78:1996;142-147.
68. Pollak H, Fischer M, Fritsch S, Enenkel W. Are admission plasma fibrinogen levels useful in the characterization of risk groups after myocardial infarction treated with fibrinolysis? Thromb Haemost. 66:1991;406-409.
69. Morrow D, Rifai N, Antman E. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes. J Am Coll Cardiol. 31:1998;1460-1465.
70. Kuller L, Tracy R, Shaten J. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 144:1996;537-547.
71. Ardission D, Merlini P, Gamba G. Thrombin activity and early outcome in unstable angina. Circulation. 93:1996;1634-1639.
72. Ernofsson M, Strekerud F, Toss H, Abildgaard U, Wallentin L, Siegbahn A. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost. 79:1998;491-494.
73. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 342:1993;1076-1079.
74. Meade TW. Routine measurement of fibrinogen concentration. Clinically feasible [letter; comment]. Br Med J. 307:1993;1562.
75. Meade TW. Fibrinogen in ischaemic heart disease. Eur Heart J. 16:1995;31-35.
76. Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J. 11:1990;525-528.
77. Hamsten A, Walldius G, Szamosi A. Plasminogen activator in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;3-8.
78. Kruskal JCP, Franks J, Kirsch R. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med. 22:1987;1361-1365.
79. Wilcox I, Freedman SB, Allman KC. Prognostic significance of a predischarge exercise test in risk stratification after unstable angina pectoris. J Am Coll Cardiol. 18:1991;677-683.
80. Wilcox I, Freedman SB, Li JN, Harris PJ, Kelly DT. Comparison of exercise stress testing with ambulatory electrocardiographic monitoring in the detection of myocardial ischemia after unstable angina pectoris. Am J Cardiol. 67:1991;89-91.
81. Launbjerg J, Fruergaard P, Jacobsen HL, Madsen JK. Long-term risk factors from non-invasive evaluation of patients with acute chest pain, but without myocardial infarction. Eur Heart J. 16:1995;30-37.
82. Nyman I, Wallentin L, Areskog M, Areskog NH, Swahn E. Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group. Int J Cardiol. 39:1993;131-142.
83. Amanullah AM, Lindvall K, Bevegard S. Exercise echocardiography after stabilization of unstable angina: correlation with exercise thallium-201 single photon emission computed tomography. Clin Cardiol. 15:1992;585-589.
84. Amanullah AM, Lindvall K. Predischarge exercise echocardiography in patients with unstable angina who respond to medical treatment. Clin Cardiol. 15:1992;417-423.
85. Amanullah AM, Lindvall K, Bevegard S. Prognostic significance of exercise thallium-201 myocardial perfusion imaging compared to stress echocardiography and clinical variables in patients with unstable angina who respond to medical treatment. Int J Cardiol. 39:1993;71-78.
86. Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging in patients with unstable angina who respond to medical treatment. J Am Coll Cardiol. 17:1991;1053-1057.
87. Luchi R, Scott, Deupree. Comparison of medical and surgical treatment for unstable angina pectoris. N Engl J Med. 316:1987;977-984.
88. Gottlieb S, Weisfeldt ML, Ouyang P. Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: a randomized, double-blind, placebo-controlled trial. Circulation. 73:1986;331-337.
89. Telford A, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet. 1:1981;1225-1228.
90. Lubsen JTJ. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol. 60:1987;18A-25A.
91. Yusuf S, Witte J, Friedman L. Overview of results of randomized trials in heart disease: unstable angina, heart failure, primary prevention with aspirin and risk factor modifications. JAMA. 260:1988;2259-2263.
92. Eur Heart J. 6:1985;199-226.
93. DePace N, Herling IM, Kotler MN, Hakki AH, Spielman SR, Segal BL. Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action. Arch Intern Med. 142:1982;1806-1809.
94. Kaplan K, Davison R, Parker M, Przybylek J, Teagarden JRML. Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy. Am J Cardiol. 51:1983;694-698.
95. Roubin G, Harris PJ, Eckhardt I. Intravenous nitroglycerine in refractory unstable angina pectoris. Aust NZ J Med. 12:1982;598-602.
96. Curfman G, Heinsimr JA, Lozner EC, Fung HL. Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: a prospective randomized trial. Circulation. 67:1983;276-282.
97. Dellborg M, Gustafsson G, Swedberg K. Buccal versus intravenous nitroglycerin in unstable angina pectoris. Eur J Clin Pharmacol. 41:1991;5-9.
98. May DCPJ, Black WH. In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med. 317:1987;805-809.
99. Reichek N, Priest C, Zimrin D, Chandler T, Sutton MS. Antianginal effects of nitroglycerin patches. Am J Cardiol. 54:1984;1-7.
100. Thadani U, Hamilton SF, Olsen E. Transdermal nitroglycerin patches in angina pectoris. Dose titration, duration of effect, and rapid tolerance. Ann Intern Med. 105:1986;485-492.
101. Theroux P, Taeymans Y, Morissette D. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol. 5:1985;717-722.
102. Parodi OSI, Michelassi C. Comparison of verapamil and propanolol therapy for angina pectoris at rest. A randomized, multiple crossover, controlled trial in the coronary care unit. Am J Cardiol. 57:1986;899-906.
103. Smith NLRG, Psaty BM. Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina. J Am Coll Cardiol. 32:1998;1305-1311.
104. Held PYS, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J. 299:1989;1187-1192.
105. Psaty BM, Heckbert SR, Koepsell TD. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 274:1995;620-625.
106. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 67:1991;1295-1297.
107. Boden W, Van Gilst W, Scheldewaert R. Secondary prevention with diltiazem once daily versus placebo in patients with acute myocardial infarction treated with thrombolysis. Lancet. 2000.
108. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 276:1996;811-815.
109. Theroux P, Ouimet H, McCans J. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 319:1988;1105-1111.
110. Lancet. 347:1996;561-568.
111. Klein W, Buchwald A, Hillis SE. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation. 96:1997;61-68.
112. Antman EM. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators. Am Heart J. 135:1998;S353-60.
113. Antman EM, Cohen M, Radley D. Assessment of the treatment effect of enoxaparin for unstable Angina/ Non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation. 100:1999;1602-1608.
114. Eur Heart J. 20:1999;1553-1562.
115. N Engl J Med. 335:1996;775-782.
116. Fox KA. Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials. Am J Cardiol. 84:1999;26M-31M.
117. Lancet. 336:1990;827-830.
118. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 88:1993;2045-2048.
119. Cairns JA, Singer J, Gent M. One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000 people. Can J Cardiol. 5:1989;239-246.
120. Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden [comment]. J Am Coll Cardiol. 18:1991;1587-1593.
121. Balsano F, Violi F, Cimminiello C. Ticlopidine in unstable angina. Circulation. 82:1990;2282-2283.
122. Balsano F, Rizzon P, Violi F. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation. 82:1990;17-26.
123. Lancet. 348:1996;1329-1339.
124. Bertrand M, Legrand V, Boland J. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (Fantastic) study. Circulation. 98:1998;1597-1603.
125. Schömig A, Neumann FJ, Kastrati A. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery. N Engl J Med. 334:1996;1084-1089.
126. Leon M, Baim DS, Popma JJ. A clinical trial comparing three antithrombotic-drug regimens after coronaryartery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 339:1998;1665-1671.
127. Bertrand M, Rupprecht H, Urban P, Gershlick A. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin combined with ticlopidine in combination with aspirin after coronary stenting. Circulation. 2000.
128. Alexander JH, Al-Khatib S, Cantor W. Highlights from the American College of Cardiology 48th Annual Scientific Sessions: March 7 to 10, 1999. Am Heart J. 138:1999;175-190.
129. Lancet. 349:1997;1429-1435.
130. N Engl J Med. 338:1998;1498-1505.
131. N Engl J Med. 338:1998;1488-1497.
132. Circulation. 97:1998;2386-2395.
133. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 100:1999;2045-2048.
134. N Engl J Med. 330:1994;956-961.
135. N Engl J Med. 336:1997;1689-1696.
136. Lancet. 352:1998;87-92.
137. Lancet. 349:1997;1422-1428.
138. Circulation. 96:1997;1445-1453.
139. Brener SJ, Barr LA, Burchenal JE, Wolski KE, Effron MB, Topol EJ. Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. Am J Cardiol. 84:1999;728-730.
140. N Engl J Med. 339:1998;436-443.
141. N Engl J Med. 338:1998;1488-1497.
142. Lancet. 355:2000;337-345.
143. Circulation. 87:1993;38-52.
144. Karlsson JE, Berglund U, Bjorkholm A, Ohlsson J, Swahn E, Wallentin L. Thrombolysis with recombinant human tissue-type plasminogen activator during instability in coronary artery disease: effect on myocardial ischemia and need for coronary revascularization. TRIC Study Group. Am Heart J. 124:1992;1419-1426.
145. Schreiber TL, Macina G, McNulty A. Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave myocardial infarction. Am J Cardiol. 64:1989;840-844.
146. Schreiber TL, Macina G, Bunnell P. Unstable angina or non-Q wave infarction despite long-term aspirin: response to thrombolytic therapy with implications on mechanisms. Am Heart J. 120:1990;248-255.
147. Schreiber TL, Rizik D, White C. Randomized trial of thrombolysis versus heparin in unstable angina. Circulation. 86:1992;1407-1414.
148. Lancet. 343:1994;311-322.
149. Yusuf S, Flather M, Pogue J. Variations between countries in invasive and cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet. 352:1998;507-514.
150. Boden WE, O'Rourke RA, Crawford MH. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. 338:1998;1785-1792.
151. Lancet. 354:1999;708-715.
152. Van Belle E, Lablanche JM, Bauters C, Renaud N, McFadden EP, Bertrand ME. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. Circulation. 97:1998;26-33.
153. Serruys PW, van Hout B, Bonnier H. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 352:1998;673-681.
154. Lincoff AM. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Am J Cardiol. 82:1998;36P-42P.
155. Lincoff AM, Califf RM, Anderson KM. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol. 30:1997;149-156.
156. Ahmed WH, Bittl JA, Braunwald E. Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparison with that in stable angina. Am J Cardiol. 72:1993;544-550.
157. Rahimtoola SH, Fessler CL, Grunkemeier GL, Starr A. Survival 15 to 20 years after coronary bypass surgery for angina. J Am Coll Cardiol. 21:1993;151-157.
158. Naunheim KS, Fiore AC, Arango DC. Coronary artery bypass grafting for unstable angina pectoris: risk analysis. Ann Thorac Surg. 47:1989;569-574.
159. Yusuf S, Zucker D, Peduzzi P. Effects of CABG on survival: overview of 10-year results from randomised trials. Lancet. 344:1994;563-567.
160. JAMA. 277:1997;715-721.
161. Circulation. 93:1996;847.
162. Lancet. 341:1993;573-580.
163. King SB 3rd, Lembo NJ, Weintraub WS. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med. 331:1994;1044-1050.
164. Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med. 331:1994;1037-1043.
165. Rodriguez A, Boullon F, Perez-Balino N, Paviotti C, Liprandi MI, Palacios IF. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group. J Am Coll Cardiol. 22:1993;1060-1067.
166. Lancet. 354:1999;708-715.
167. Kontny F. Reactivation of the coagulation system: rationale for long-term antithrombotic treatment. Am J Cardiol. 80:1997;55E-60E.
168. Chen L, Chester MR, Redwood S, Huang J, Leatham E, Kaski JC. Angiographic stenosis progression and coronary events in patients with 'stabilized' unstable angina. Circulation. 91:1995;2319-2324.
169. Merlini PA, Bauer KA, Oltrona L. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 90:1994;61-68.
170. Lancet. 344:1994;1383-1389.
171. Rossouw JE. Lipid-lowering interventions in angiographic trials. Am J Cardiol. 76:1995;86C-92C.
172. Pfeffer MA, Braunwald E, Moye LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 327:1992;669-677.
173. N Engl J Med. 325:1991;293-302.
174. N Engl J Med. 327:1992;685-691.
175. Collins R, Peto R, MacMahon S. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 335:1990;827-838.
176. Rabbani RTE. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res. 41:1999;402-417.
177. Yusuf S, Kostis JB, Pitt B. ACE inhibitors for myocardial infarction and unstable angina [letter; comment]. Lancet. 341:1993;829.
178. N Engl J Med. 342:2000;145-153.
179. Yusuf S, Lonn E. Anti-ischemic effects of ACE inhibitors: review of current clinical evidence and ongoing trials. Eur Heart J. 19:1998;36-44.
180. Specchia GDSS, Falcone C, Bramucci E. Coronary arterial spasm as a cause of exercise-induced ST segment elevation in patients with variant angina. Circulation. 59:1979;948-954.
181. De Servi SAE, Marsico F, Bramucci E. Correlation between clinical and morphologic findings in unstable angina. Am J Cardiol. 77:1996;128-132.
182. Bertrand M, Lablanche J, Tilmant P. Frequency of provoked coronary arterial spasm in 1,089 consecutive patients undergoing coronary arteriography. Circulation. 65:1982;1299-1306.
183. Previtali MAD, Barberis P, Panciroli C, Chimienti M, Salerno JA. Hyperventilation and ergonovine Tests in Prinzmetal's Variant Angina Pectoris in Men. Am J Cardiol. 63:1989;17-20.
184. Previtali MPC, De Ponti R, Chimienti M, Montemartini C, Salerno JA. Time-related decrease in sensitivity to ergonovine in patients with variant angina. Am Heart J. 117:1989;92-99.
185. Yasue HWM, Omote S, Takizawa K, Tanaka S. Coronary arterial spasm and Prinzmetal's variant angina reduced by hyperventilation and Tris-Buffer infusion. Circulation. 58:1978;56-62.
186. Severi S, Davies G, Maseri AMP, L'Abbate, A. Long-term prognosis of 'variant' angina with medical treatment. Am J Cardiol. 46:1980;226-232.
187. Bory M, Pierron F, Panagides D, Bonnet J. Coronary artery spasm in patients with normal or near normal coronary arteries. Eur Heart J. 17:1996;1015-1021.
188. Rovai DB, Baratto M. Organic coronary stenosis in Prinzemetal's variant angina. J Cardiol. 30:1997;299-305.
189. Scholl JMVP, Benacerraf A, Brau J, Hennetier G, Achard F. Long-term prognosis of medically treated patients with vasospastic angina and no fixed significant coronary atherosclerosis. Am Heart J. 115:1988;559-564.
190. Hannebicque G, Lablanche J, Gommeaux A, Fourrier J, Bertrand M. Pronostic à long terme du spasme artériel coronaire. Arch Mal Coeur. 83:1990;461-467.